AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23646111
Drug: Stable combination
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable combination antiretroviral therapy (Black ethnicity)
Trial: 23646111
Drug: Stable combination
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable combination antiretroviral therapy (Caucasian ethnicity, demographically adjusted)
Trial: 23646111
Drug: Stable combination
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable combination antiretroviral therapy (Black ethnicity, demographically adjusted)
Trial: 23647688
Drug: Sustained-release acetaminophen
RxNorm normalized name: acetaminophen Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release acetaminophen
Trial: 23647688
Drug: Medication factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication factors (side effects, out-of-pocket costs, mode of action, treatment schedule)
Trial: 23652269
Drug: Dalfampridine (0.5-2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine (0.5-2.0 mg/kg)
Trial: 23659317
Drug: Nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (125 mg/m2) and cisplatin (75 mg/m2) combination therapy
Trial: 23660579
Drug: Serum-derived bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum-derived bovine immunoglobulin (SBI) 2.5 g twice daily for 8 weeks
Trial: 23663091
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly (3-month prospective period)
Trial: 23663490
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment for bipolar disorder
Trial: 23663490
Drug: Medication use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication use during episodes
Trial: 23664013
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) given concurrently with chemotherapy for a total of eight doses over 36 weeks.
Trial: 23664013
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) combined with conventional chemotherapy.
Trial: 23664414
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment for 8 weeks
Trial: 23664596
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg/d for 7 days
Trial: 23664596
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil 4 g/day for 28 days
Trial: 23664596
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin and fish oil for 7 days
Trial: 23664596
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin and fish oil
Trial: 23665950
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg/day on Schedule 2/2 plus S-1 (80-120 mg/day)/cisplatin 60 mg/m²
Trial: 23665950
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg/day on continuous daily dosing (CDD)
Trial: 23665950
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg/day on Schedule 2/2
Trial: 23665950
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/day on Schedule 2/2
Trial: 23665950
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen (sunitinib plus S-1/cisplatin)
Trial: 23666316
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg QW + MTX for 36 weeks
Trial: 23666573
Drug: Theophylline dosing
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline dosing regimen (exact dosage not specified)
Trial: 23667266
Drug: 3-dose quadrivalent
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose quadrivalent HPV vaccine series (HPV-6, -11, -16, -18)
Trial: 23667487
Drug: Lapatinib 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1500 mg daily
Trial: 23668924
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (mean dose 2.4±1.4 mg/24 h)
Trial: 23668924
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (starting doses: 1 mg/24 h for 85% of de novo patients, 1 mg/24 h for 50% of pretreated patients, 2 mg/24 h for 40% of pretreated patients)
Trial: 23669289
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) for 48 weeks
Trial: 23669289
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir)
Trial: 23675632
Drug: 0.25% miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% miconazole nitrate ointment (7-day course)
Trial: 23676114
Drug: Intravenous anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous anidulafungin for at least 5 days, optionally followed by oral voriconazole
Trial: 23676114
Drug: Intravenous anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous anidulafungin
Trial: 23676799
Drug: Self-empowerment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-empowerment group treatment
Trial: 23676799
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy and medical examinations
Trial: 23678005
Drug: Intermittent imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent imatinib (IM) therapy for 1 month on and 1 month off
Trial: 23678006
Drug: Tocilizumab (IL-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (IL-6 receptor-directed therapy)
Trial: 23678376
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (50 mg in an excipient solution applied as a spray to the oropharynx)
Trial: 23678376
Drug: Placebo (taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (taste excipients solution without active substance)
Trial: 23680457
Drug: Creatine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (20 g/d for 5 d followed by 5 g/d throughout the trial)
Trial: 23680957
Drug: Thrombolytic agents
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agents administered during or after the procedure
Trial: 23682558
Drug: Anti-transforming growth
RxNorm normalized name: Anti-transforming growth factor-beta monoclonal antibody 2G7
DrugBank: 2G7 (DB18589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-transforming growth factor-β therapy
Trial: 23684555
Drug: Two 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 150 g portions of farmed salmon per week
Trial: 23685546
Drug: GSK1360707 (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1360707 (novel triple reuptake inhibitor)
Trial: 23686466
Drug: Adalimumab after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab after drug withdrawal and retreatment
Trial: 23687088
Drug: B7-H6 induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B7-H6 induction in vitro by Toll-like receptor ligands or proinflammatory cytokines
Trial: 23687572
Drug: 0.50-mL dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Trial: 23687572
Drug: 0.25-mL dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Trial: 23688169
Drug: Inhaled budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide, 400 ug twice daily for twelve weeks
Trial: 23689994
Drug: Subconjunctival Palomid
RxNorm normalized name: Palomid 529
DrugBank: Palomid 529 (DB12812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival Palomid 529 (1.9 mg)
Trial: 23692690
Drug: Non-invasive foot-worn
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive foot-worn biomechanical device (AposTherapy) used daily during regular activities
Trial: 23694831
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of OKA/GSK varicella vaccine
Trial: 23694831
Drug: Any varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any varicella vaccine (including OKA/GSK, OKA/Merck, MMR-OKA/GSK)
Trial: 23697705
Drug: Serum 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) concentrations <10 ng/mL
Trial: 23697705
Drug: Serum 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥10 to <20 ng/mL
Trial: 23697705
Drug: Serum 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥20 ng/mL (highest category)
Trial: 23698253
Drug: Temsirolimus 15
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 15 mg IV weekly and Pazopanib 400 mg orally daily
Trial: 23698253
Drug: Temsirolimus 10
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 10 mg IV weekly and Pazopanib 200 mg orally daily
Trial: 23698253
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of temsirolimus and pazopanib
Trial: 23700789
Drug: L-NAME 0
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME 0 mg.kg-1 (Control)
Trial: 23700789
Drug: L-NAME 1
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME 1 mg.kg-1
Trial: 23700789
Drug: L-NAME 2
RxNorm normalized name: β-L-2'-deoxythymidine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-NAME 2 mg.kg-1
Trial: 23700789
Drug: L-NAME 4
RxNorm normalized name: 4-hydroxy-L-phenylalanine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-NAME 4 mg.kg-1
Trial: 23701810
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment (antidepressants, anticonvulsants, opiates)
Trial: 23701810
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with 5% lidocaine medicated plaster
Trial: 23701891
Drug: Integrative cognitive-affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative cognitive-affective therapy (ICAT)
Trial: 23701891
Drug: Enhanced cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive-behavioral therapy (CBT-E)
Trial: 23703723
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss intervention (exercise, behavior, and nutrition therapy)
Trial: 23706985
Drug: Nab-paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel at 260 mg/m(2) intravenously every 3 weeks.
Trial: 23707169
Drug: F4/AS01 candidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F4/AS01 candidate vaccine
Trial: 23710653
Drug: IV anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV anidulafungin followed by oral voriconazole
Trial: 23710698
Drug: Vaginal dilators,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal dilators, topical corticosteroids, and estrogen for vaginal cGVHD.
Trial: 23715103
Drug: Regular plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular plasma treatment for hereditary TTP
Trial: 23715577
Drug: Dasatinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (60 to 120 mg/m(2) once daily)
Trial: 23716538
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/day orally on days 1 - 21 (28-day cycle); melphalan 0.18 mg/kg orally on days 1-4; dexamethasone 40 mg orally on days 1, 8, 15, and 22
Trial: 23716541
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m(2))
Trial: 23719348
Drug: Efavirenz, didanosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz, didanosine, and lamivudine (combined therapy)
Trial: 23719651
Drug: Uniblocker® inserted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniblocker® inserted into the endotracheal tube and advanced until the blocker balloon just protruded from the endotracheal tube tip
Trial: 23719719
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg by intravenous infusion every 3 weeks for up to 16 cycles)
Trial: 23720019
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with full-dose gemcitabine (1 g/m(2) over 30 minutes on days 1, 8, and 15) and oxaliplatin (85 mg/m(2) on days 1 and 15) with radiation therapy (30 Gray in 2-Gy fractions during cycle 1)
Trial: 23720019
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with full-dose gemcitabine, oxaliplatin, and RT
Trial: 23720182
Drug: Monotherapy for
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy for PAH
Trial: 23720182
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy for PAH
Trial: 23720182
Drug: No PAH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PAH drugs
Trial: 23722308
Drug: Immunocryosurgery (liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunocryosurgery (liquid nitrogen, open spray, 2 × 15 s; day 14) during 5 weeks' imiquimod
Trial: 23725004
Drug: AllerT (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AllerT (combination of three COPs selected for undetectable IgE binding)
Trial: 23726000
Drug: 3D-CRT (38.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D-CRT (38.5 Gy in 10 fractions twice daily over 5 days)
Trial: 23726267
Drug: Tivozanib 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 0.5, 1.0 or 1.5mg/d orally (3 weeks on/1 week off) and temsirolimus 15 or 25 mg/week intravenously
Trial: 23726971
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m(2) + cisplatin 75 mg/m(2) + cetuximab 250 mg/m(2) (loading dose: 400 mg/m(2))
Trial: 23726971
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Platinum/5-fluorouracil plus cetuximab)
Trial: 23729989
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of presenting anxiety disorder
Trial: 23731330
Drug: Maraviroc plus
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc plus optimized background therapy (OBT)
Trial: 23731760
Drug: MSCs treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSCs treatment
Trial: 23731760
Drug: Immunological analysis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunological analysis post-MSC treatment
Trial: 23731832
Drug: Lenalidomide 25mg
RxNorm normalized name: LENALIDOMIDE 25MG CAP,ORAL
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months
Trial: 23732043
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (PI and NNRTI)
Trial: 23733041
Drug: Two-dose rotavirus
RxNorm normalized name: ROTAVIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Vaccines)
Trial: 23733198
Drug: Non-ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ACE inhibitors
Trial: 23733473
Drug: PaMZ (PA-824-moxifloxacin-pyrazinamide)
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PaMZ (PA-824-moxifloxacin-pyrazinamide) given at human-equivalent doses 5 days/week for 8 weeks
Trial: 23733473
Drug: Both combination
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both combination regimens (PaMZ and RHZ)
Trial: 23733802
Drug: No mTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mTOR inhibitor treatment (Control)
Trial: 23733925
Drug: (99m)Tc-labeled PSMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc-labeled PSMA inhibitors
Trial: 23735702
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) at a dose of 40 mg/m² every 28 days for six courses
Trial: 23737404
Drug: Lacosamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (100 mg single oral dose)
Trial: 23738760
Drug: Pre-transplant infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-transplant infusion of autologous MSC
Trial: 23738760
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy without basiliximab
Trial: 23739218
Drug: Fasting glucose
RxNorm normalized name: FAST TAKE (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose >7.0 mmol/l
Trial: 23739218
Drug: Fasting glucose
RxNorm normalized name: FAST TAKE (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose between 6.1 and 7.0 mmol/l
Trial: 23739218
Drug: Fasting glucose
RxNorm normalized name: FAST TAKE (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose <6.1 mmol/l
Trial: 23740728
Drug: Enzyme immunoassay
RxNorm normalized name: snake venom detection kit, enzyme immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme immunoassay kit detecting serum IgA antibody to glycopeptidolipid core antigen from MAC
Trial: 23743475
Drug: New generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generation of HCV-specific antiviral drugs
Trial: 23744583
Drug: Cranial radiation
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial radiation therapy (CRT)
Trial: 23746966
Drug: MSC1992371A (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 37 mg/m(2)/day (days 1-3 and 8-10)
Trial: 23746966
Drug: MSC1992371A (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 28 mg/m(2)/day (days 1-6)
Trial: 23750331
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg) with THC/CBD spray (10.8/10 mg)
Trial: 23750331
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg) with THC/CBD spray (10.8/10 mg)
Trial: 23750331
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg) with THC/CBD spray (10.8/10 mg)
Trial: 23751980
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) - aspirin plus an NAAA
Trial: 23751980
Drug: Nonaspirin antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonaspirin antiplatelet agents (NAAAs)
Trial: 23751980
Drug: Nonusers (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers (no antiplatelet drugs)